Case Report
Recurrent Anemia and Fever in a Young Male with Sickle Cell Disease and Bioprosthetic Valves: A Diagnostic Challenge in a Resource-Limited Setting
- Shabbir Moizali Walijee *
Tanga Regional Referral Hospital, Tanga, Tanzania.
*Corresponding Author: Shabbir Moizali Walijee, Tanga Regional Referral Hospital, Tanga, Tanzania.
Citation: : Shabbir M. Walijee. (2025). Recurrent Anemia and Fever in a Young Male with Sickle Cell Disease and Bioprosthetic Valves: A Diagnostic Challenge in a Resource-Limited Setting. Clinical Case Reports and Studies, BioRes Scientia Publishers. 10(5):1-2. DOI: 10.59657/2837-2565.brs.25.274
Copyright: © 2025 Shabbir Moizali Walijee, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: August 22, 2025 | Accepted: September 05, 2025 | Published: September 12, 2025
Abstract
We report a challenging case of a 25-year-old male with homozygous sickle cell disease (SCD) and a history of bioprosthetic aortic and mitral valve replacement for rheumatic heart disease (RHD), performed 12 years ago. The patient presented to Tanga Regional Referral Hospital with recurrent anemia, exertional dyspnea, and low-grade fever, without jaundice. Notably, he had never been on anticoagulation post-surgery. The facility lacked both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE), and a direct Coombs test was not available. He was managed empirically with ceftriaxonesulbactam and supportive care. This case emphasizes the complexities of managing overlapping chronic diseases and prosthetic valve complications in low-resource settings where standard diagnostic modalities are not accessible.
Keywords: sickle cell disease; bioprosthetic valves; rheumatic heart disease; anemia; echocardiography unavailable; resource-limited setting; ceftriaxone-sulbactam
Introduction
Sickle cell disease (SCD) and rheumatic heart disease (RHD) are both endemic in sub-Saharan Africa and may coexist in young individuals, compounding morbidity [1,2]. Bioprosthetic valves are often preferred over mechanical valves in patients unable to comply with lifelong anticoagulation or where monitoring is unavailable [3]. However, they are subject to earlier degeneration in younger patients, especially in the setting of chronic inflammation, such as that seen in SCD [4,5].
The utilityof regular echocardiographic follow-up in such patients is undisputed [6], but many institutions, including Tanga Regional Referral Hospital, lack both transthoracic (TTE) and transesophageal (TEE) echocardiography. This significantly limits diagnostic capability, particularly in evaluating potential structural valve degeneration, thrombosis, or infective endocarditis [7].
Case Presentation
A 25-year-old male with known homozygous SCD presented with fatigue, worsening exertional dyspnea, and low-grade fever for three weeks. He denied any history of jaundice, hematuria, bleeding, weight loss, or respiratory symptoms.
Past Medical History
- Diagnosed with SCD at age 2; frequent vaso-occlusive crises in childhood.
- Bioprosthetic aortic and mitral valve replacement at age 13 for RHD.
- No anticoagulation since surgery.
- No cardiac or hematologic follow-up since surgery.
Clinical Examination
- General: Pale, afebrile, no jaundice
- Vitals: BP 110/68 mmHg, HR 96 bpm, RR 20/min, SpO 94% RA
- Cardiac: Soft systolic murmur at the apex, no prosthetic clicks
- Respiratory: Clear auscultation
- Abdominal: Mild splenomegaly, no tenderness or organomegaly
- Neurological & Skin: Unremarkable
Investigations
- Hemoglobin: 6.3 g/dL
- MCV: 85 fL
- Reticulocyte Count: 5.6%
- WBC: 12,100/mm
- Platelets: 430,000/mm ESR: 65 mm/hr
- CRP: 26 mg/L
- LDH: 620 U/L
- Total Bilirubin: 1.1 mg/dL (Indirect: 0.4)
- Ferritin: 430 ng/mL Coombs Test:Not available HIV/Hepatitis B/C: Negative
- Blood Cultures: No growth after 5 days Chest X-ray: Cardiomegaly, clear lung fields TTE / TEE: Not available at our facility
Management
- 2 units of packed red blood cell transfusion
- Intravenous ceftriaxonesulbactam for 5 days empirically, then stopped after afebrile and cultures were negative
- Folic acid, hydration, and pain management
- Hydroxyurea optimization
- Initiated low-dose aspirin (75 mg daily)
- Deferred anticoagulation pending cardiac evaluation
Discussion
This case exemplifies the diagnostic uncertainty inherent in managingcomplex chronic diseasein low-resource environments.
Bioprosthetic Valve Dysfunction
Bioprosthetic valves are more prone to degeneration in young, metabolically active patients and those with chronic inflammatory states like SCD (4,5). Without TTE or TEE, we could not assess for stenosis, regurgitation, or vegetation, thus clinical judgment was crucial.
Lack of Anticoagulation and Surveillance
Although bioprosthetic valves typically do not require long-term anticoagulation, in SCD patients with increased hypercoagulability, thrombotic complications have been reported (8). The absence of any follow-up echocardiography for over a decade significantly increases the likelihood of undiagnosed valve dysfunction (6).
Recurrent Anemia and Fever in SCD
Anemia in SCD is usually multifactorial: chronic hemolysis, inflammation, nutritional deficiency, or hypersplenism (9). Absence of jaundice and normal bilirubin suggested anemia of inflammation. The raised ESR/CRP with negative cultures and resolution of fever with antibiotics suggests subclinical infection, possibly involving the valve.
Imaging Limitations
The inability to perform both TTE and TEE at Tanga Regional Referral Hospital reflects a systemic gap in regional diagnostic capacity. Even basic surveillance tools were unavailable, severely compromising care (10).
Conclusion
This case emphasizes the vulnerability of SCD patients with prosthetic heart valves in settings without echocardiographic access. The absence of anticoagulation and lack of imaging over 12 years pose serious risks of undetected valve degeneration or endocarditis. It highlights the urgent need to strengthen diagnostic capacity and establish standardized follow-up protocols in regional hospitals across Africa.
Patient Perspective
The patient reported that he believed valve surgery had "cured" his heart condition and was unaware of the need for lifelong monitoring. He expressed appreciation for the renewed attention and willingness to attend future cardiology follow-ups.
Informed Consent
Written informed consent was obtained from the patient for anonymous case publication.
References
- Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010). Sickle-cell disease. The Lancet, 376(9757):2018–2031.
Publisher | Google Scholor - Watkins, D. A., Johnson, C. O., Colquhoun, S. M., et al. (2017). Global burden of rheumatic heart disease, 1990–2015. The New England Journal of Medicine, 377(8):713–722.
Publisher | Google Scholor - Iung, B., et al. (2003). A prospective survey of patients with valvular heart disease in Europe. European Heart Journal, 24(13):1231–1243.
Publisher | Google Scholor - Bourguignon, T., et al. (2015). Very long-term outcomes of the Carpentier-Edwards valve. The Annals of Thoracic Surgery, 99(3):831–837.
Publisher | Google Scholor - Ruel, M., et al. (2005). Valve replacement outcomes in young patients. European Journal of Cardio-Thoracic Surgery, 27(3):425–433.
Publisher | Google Scholor - Zoghbi, W. A., et al. (2009). Recommendations for evaluation of prosthetic valves. Journal of the American Society of Echocardiography, 22(9):975–1014.
Publisher | Google Scholor - Li, J. S., et al. (2000). Duke criteria for infective endocarditis. Clinical Infectious Diseases, 30(4):633–638.
Publisher | Google Scholor - Ataga, K. I. (2009). Hypercoagulability in sickle cell disease. Hematology/Oncology Clinics of North America Education Program, 2009(1):54–61.
Publisher | Google Scholor - Kato, G. J., et al. (2018). Sickle cell disease. Nature Reviews Disease Primers, 4:18010.
Publisher | Google Scholor - Essien, E. O., & Thakur, R. K. (2021). Cardiovascular care in sub-Saharan Africa. Clinical Cardiology, 44(4):457–465.
Publisher | Google Scholor
